HOXC6 predicts invasion and poor survival in hepatocellular carcinoma by driving epithelial-mesenchymal transition

Li, Pindong; Chen, Peng; Peng, Xin; Ma, Charlie; Zhang, Wenjie; Dai, Xiao-Fang

doi:10.18632/aging.101363

Cited by 20 publications

(19 citation statements)

References 29 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results indicated that HOXC6 mRNA expression might be linked with poor clinical prognosis and are consistent with previous studies, which were conducted in GC and other malignant tumors such as prostate cancer, esophageal cancer and hepatocellular carcinoma [20,22,25,26]. Therefore, we conclude that HOXC6 might be a potential biomarker for predicting prognosis.…”

Section: Plos Onesupporting

confidence: 92%

Increased HOXC6 mRNA expression is a novel biomarker of gastric cancer

Jung

Jeong

et al. 2020

PLoS ONE

View full text Add to dashboard Buy / Rent full text

In this study, we aimed to investigate the molecular biomarkers that are pivotal for the development and progression of gastric cancer (GC). We analyzed clinical specimens using RNA sequencing to identify the target genes. We found that the expression of HOXC6 mRNA was upregulated with the progression of cancer, which was validated by quantitative real time PCR and RNA in-situ hybridization. To compare the protein expression of HOXC6, we evaluated GC and normal gastric tissue samples using western blot analysis and immunohistochemistry. We detected significantly higher levels of HOXC6 in the GC tissues than in the normal controls at both mRNA and protein levels. The expression levels of HOXC6 mRNA in patients with advanced gastric cancer (AGC) were significantly higher than those in patients with early gastric cancer (EGC). Kaplan-Meier curves showed that high expression of HOXC6 mRNA is significantly associated with poor clinical prognosis. Our findings suggest that HOXC6 mRNA may be a novel biomarker and can be potentially valuable in predicting the prognosis of GC patients. Especially, HOXC6 mRNA in-situ hybridization may be a diagnostic tool for predicting prognosis of individual GC patients.

show abstract

Section: Plos Onesupporting

confidence: 92%

Increased HOXC6 mRNA expression is a novel biomarker of gastric cancer

Jung

Jeong

et al. 2020

PLoS ONE

View full text Add to dashboard Buy / Rent full text

show abstract

“…Liu et al reported that ZFPM2 Antisense RNA 1 (ZFPM2-AS1) promotes tumor proliferation and inhibits apoptosis through regulating miR-137 in renal cell cancer [32]. Li et al reported that Homeobox C6 (HOXC6) promotes invasion via EMT pathway in hepatocellular carcinoma [33]. Petraki et al reported that Kallikrein Related Peptidase 10 (KLK10) expression is associated with overall survival in CRC [34].…”

Section: Discussionmentioning

confidence: 99%

Two precision medicine predictive tools for six malignant solid tumors: from gene-based research to clinical application

Zhang

Huang

et al. 2019

J Transl Med

View full text Add to dashboard Buy / Rent full text

BackgroundThe current study aimed to construct competing endogenous RNA (ceRNA) regulation network and develop two precision medicine predictive tools for colorectal cancer (CRC).MethodsDifferentially expressed (DE) analyses were performed between CRC tissues and normal tissues. A ceRNA regulation network was constructed based on DElncRNAs, DEmiRNAs, and DEmRNAs.ResultsFifteen mRNAs (ENDOU, MFN2, FASLG, SHOC2, VEGFA, ZFPM2, HOXC6, KLK10, DDIT4, LPGAT1, BEX4, DENND5B, PHF20L1, HSP90B1, and PSPC1) were identified as prognostic biomarkers for CRC by multivariate Cox regression. Then a Fifteen-mRNA signature was developed to predict overall survival for CRC patients. Concordance indexes were 0.817, 0.838, and 0.825 for 1-, 2- and 3-year overall survival. Patients with high risk scores have worse OS compared with patients with low risk scores.ConclusionThe current study provided deeper understanding of prognosis-related ceRNA regulatory network for CRC. Two precision medicine predictive tools named Smart Cancer Survival Predictive System and Gene Survival Analysis Screen System were constructed for CRC. These two precision medicine predictive tools can provide valuable precious individual mortality risk prediction before surgery and improve the individualized treatment decision-making.

show abstract

“…Notably, according to their nearby genes, the present study was also able to identify a few tumor-associated lncRNAs altered in BC. ENST00000562848, ENST00000587187, ENST00000398878, ENST00000421206, ENST00000443576 and ENST00000562393 are spliced from the neighboring areas of HOXC6 ( 58 ), UHRF1 ( 59 ), SULT1A3 ( 60 ), GRK5 ( 61 ), STARD13 ( 62 ) and BDKRB2 ( 63 ), which plays a critical role in malignant proliferation, migration and metastasis. Overall, these findings indicated that these lncRNAs are associated with a diverse range of different types of cancer, thereby emphasizing the accuracy of the sequencing data in the present study, and indicating the potential critical role of these lncRNAs in the development of BC as well.…”

Section: Discussionmentioning

confidence: 99%

Long noncoding RNAs, ENST00000598996 and ENST00000524265, are correlated with favorable prognosis and act as potential tumor suppressors in bladder cancer

Shen

Wang

et al. 2020

Oncol Rep

View full text Add to dashboard Buy / Rent full text

Bladder cancer (BC) is a serious malignancy worldwide due to its distant metastasis and high recurrence rates. Increasing evidence has indicated that dysregulated long non-coding RNAs (lncRNAs) are involved in tumorigenesis and progression in multiple malignancies. However, their clinical significances, biological functions and molecular mechanisms in BC remain poorly understood. Hence, the present study investigated the expression profile of lncRNAs and mRNAs in five BC tissues and the corresponding adjacent normal specimens using high-throughput RNA sequencing (RNA-seq). A total of 103 differentially expressed (DE) lncRNAs were identified, including 35 upregulated and 68 downregulated ones in BC tissues. Similarly, a total of 2,756 DE-mRNAs were detected, including 1,467 upregulated and 1,289 downregulated. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses, and lncRNA-miRNA-mRNA network analyses suggested that these dysregulated lncRNAs are potentially implicated in the onset and progression of BC. Subsequently, four lncRNAs (upregulated ENST00000433108; downregulated ENST00000598996, ENST00000524265 and ENST00000398461) and two mRNAs (upregulated CCNB1 and CDK1) in 64 pairs of BC and adjacent normal tissues and four BC cell lines were detected using reverse transcription-quantitative PCR and these results were consistent with the sequencing data. Additionally, Fisher's exact test, Kaplan-Meier plots, and Cox regression analyses were used for elucidating the clinical values of ENST00000598996 and ENST00000524265. Furthermore, a receiver operating characteristic curve was constructed to assess their diagnostic values. The low expression level of ENST00000598996 and ENST00000524265 was correlated with unfavorable clinicopathological parameters, and shorter progression-free and overall survival time, whereas, ENST00000433108 was not associated with either. The in vitro functional experiments also revealed that the overexpression of ENST00000598996 and ENST00000524265 decreased the proliferation, migration, and invasion abilities of BC cells. Collectively, the results of the present study provide a novel landscape of lncRNA and mRNA expression profiles in BC. In addition, the results also indicated that ENST00000598996 and ENST00000524265 may serve as tumor suppressors, potential diagnostic biomarkers and prognostic predictors for patients with BC.

show abstract

HOXC6 predicts invasion and poor survival in hepatocellular carcinoma by driving epithelial-mesenchymal transition

Cited by 20 publications

References 29 publications

Increased HOXC6 mRNA expression is a novel biomarker of gastric cancer

Increased HOXC6 mRNA expression is a novel biomarker of gastric cancer

Two precision medicine predictive tools for six malignant solid tumors: from gene-based research to clinical application

Long noncoding RNAs, ENST00000598996 and ENST00000524265, are correlated with favorable prognosis and act as potential tumor suppressors in bladder cancer

Contact Info

Product

Resources

About